Published in Vaccine Weekly, November 16th, 2005
The double-blind, placebo-controlled phase 2 study will enroll a total of 480 healthy volunteers who will be randomized 1:1 to receive either vaccine or placebo. The treatment group will receive a DNA plasmid injection (the "prime") followed by the adenovector-based booster vaccine. Both vaccines contain DNA segments from the three major HIV subtypes,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.